Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase 1/2 Inhibitor, in Adults with Alopecia Areata: Results from the THRIVE-AA2 Phase 3, Randomized, Double-Blind, Controlled Trial

The study evaluated the efficacy and safety of deuruxolitinib, a selective Janus kinase 1/2 inhibitor, in treating adults with severe chronic alopecia areata (AA). In a randomized, double-blind, placebo-controlled trial involving 517 patients, deuruxolitinib was administered at doses of 8 mg and 12 mg twice daily. At Week 24, 33.0% of patients on 8 mg and 38.3% on 12 mg achieved significant hair regrowth (SALT score ≤20), compared to only 0.8% in the placebo group, demonstrating a statistically significant improvement (P < .0001). The treatment was well tolerated with mostly mild or moderate adverse events. However, the study did not assess long-term efficacy and safety, indicating a need for further research. Overall, deuruxolitinib shows promise as a treatment option for adults with AA.